Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology

Diagnostic Microbiology and Infectious Disease

Volumn 64, Issue 2, 2009, Pages 146-151

  Pappalardo, Mara C S M ^a   Szeszs, Maria Walderez ^b   Martins, Marilena A ^b   Baceti, Liliana B ^b   Bonfietti, Lucas X ^b   Purisco, Sonia U ^b   Baez, Andrés A ^b   Melhem, Marcia S C ^b  

^a INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

Amphotericin B; Cryptococcus neoformans; Fungicidal activity; MIC; Time kill study

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; FLUCONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANALYTIC METHOD; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BRAZIL; CLINICAL ARTICLE; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG CHOICE; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; BRAZIL; COLONY COUNT, MICROBIAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; TIME FACTORS;

EID: 67349127526     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.02.007     Document Type: Article

References (29)

1. Brouwer A.E., Teparrukkul P., Pinpraphaporn S., Larsen R.A., Chierakul W., Peacock S., et al. Baseline correlation and comparative kinetics of cerebrospinal colony-forming unit counts and antigen titers in cryptococcal meningitis. J. Infect. Dis. 192 (2005) 681-684
2. Burgess D.S., and Hastings R.W. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology. Diagn. Microbiol. Infect. Dis. 38 (2000) 87-93
3. Dannaoui E., Abdul M., Arpin M., Michel-Nguyen A., Piens M.A., Favel A., and French Cryptococcosis Study Group. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob. Agents Chemother. 50 (2006) 2464-2470
4. Dias A.L.T.D., Matsumoto F.E., Melhem M.S.C., Silva E.G., Auler M.E., Siqueira A.M., and Paula C.R. Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates. J. Med. Microbiol. 55 (2006) 1693-1699
5. Ernst E.J., Yodoi K., Roling E.E., and Klepser M.E. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, E-test, and time-kill methods. Antimicrob. Agents Chemother. 46 (2002) 578-581
6. Gomez-Lopez A., Zaragoza O., Anjos-Martins M., Melhem M.C., Rodriguez-Tudela J.L., and Cuenca-Estrella M. In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin. Microbiol. Infect. 14 (2008) 727-730
7. Kaplan J.E., Hanson D., Dworkin M.S., Frederick T., Bertolli J., Lindegren M.L., et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 30 (2000) S5-S14
8. Keele D.J., DeLallo V.C., Lewis R.E., Ernst E.J., and Klepser M.E. Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology. Diagn. Microbiol. Infect. Dis. 41 (2001) 121-126
9. Klepser M.E., Wolfe E.J., Jones R.N., Nightingale C.H., and Pfaller M.A. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41 (1997) 1392-1395
10. Klepser M.A., Ernst E.J., Lewis R.E., Ernst M.E., and Pfaller M.A. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42 (1998) 1207-1212
11. Klepser M.E., Malone D., Lewis R.E., Ernst E.J., and Pfaller M.A. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob. Agents Chemother. 44 (2000) 1917-1920
12. Larsen R.A., Bauer M., Thomas A.M., Sanchez A., Citron D., Rathbun M., and Harrison T.S. Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans. Antimicrob. Agents Chemother. 49 (2005) 3297-3301
13. Lozano-Chiu M., Paetznick V.L., Ghannoum M.A., and Rex J.H. Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J. Clin. Microbiol. 36 (1998) 2817-2822
14. Martins M.A., Pappalardo M.C.S.M., Melhem M.S.C., and Pereira-Chioccola V.L. Molecular diversity of serial Cryptococcus neoformans isolates from AIDS patients in the city of São Paulo, Brazil. Mem. Inst. Oswaldo Cruz 102 (2007) 777-783
15. Mirza S.A., Phelan M., Rimland D., Graviss E., Hamill R., et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1999-2000. Clin. Infect. Dis. 36 (2003) 789-794
16. Moraes E.M., Primola N.S., and Hamdan J.S. Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques. Mycoses 46 (2003) 164-168
17. National Committee for Clinical Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard -. 2nd ed., M27-A2 (2002), NCCLS, Wayne, PA
18. Nooney L., Matthews R.C., and Burnie J.P. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn. Microbiol. Infect. Dis. 51 (2005) 19-29
19. Pappalardo M.C.S.M., and Melhem M.S.C. Cryptococcosis: a review of the Brazilian experience for the disease. Rev. Inst. Med. Trop. Sao Paulo 45 (2003) 299-305
20. Pappalardo M.C.S.M., Paschoal R., and Melhem M.S.C. AIDS-associated central nervous system cryptococcosis: a Brazilian case study. Research Letters. AIDS 21 (2007) 1971-1972
21. Pfaller M.A., and Yu W.L. Antifungal susceptibility testing. New technology and clinical applications. Infect. Dis. Clin. North Am. 15 (2001) 1227-1261
22. Rex J.H., Cooper Jr. C.R., Merz W.G., Galgiani J.N., and Anaissie E.J. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob. Agents Chemother. 39 (1995) 906-909
23. Rex J.H., Pfaller M.A., Galgiani J.N., Bartlett M.S., Espinel-Ingroff A., Ghannoum M.A., and the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and C infections. Clin. Infect. Dis. 24 (1997) 235-247
24. Rodero L., Cordoba S., Cahn P., Hochenfellner F., Davel G., et al. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy. J. Antimicrob. Chemother. 45 (2000) 239-242
25. Rodero L., Cordoba S., Cahn P., Soria M., Lucarini M., Davel G., et al. Time-kill curves for Cryptococcus neoformans isolated from patients with AIDS. Med. Mycol. 38 (2000) 201-207
26. Saag M.S., Graybill R.J., Larsen R.A., Pappas P.G., Perfect J.R., et al. Practice guidelines for the management of cryptococcal disease. Clin. Infect. Dis. 30 (2000) 710-718
27. Sacktor N., Lyles R.H., Skolasky R., Kleeberger C., Selnes O.A., Miller E.N., et al. HIV-associated neurologic disease incidence changes: multicenter Aids cohort study, 1990-1998. Neurology 56 (2001) 257-260
28. Vanden Bossche H., Dromer F., Improvisi I., Lozano-Chiu M., Rex J.H., and Sanglard D. Antifungal drug resistance in pathogenic fungi. Med. Mycol. 36 (1998) 119-128
29. Warnock D.W., Johnson E.M., Rogers T.R., et al. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. J. Antimicrob. Chemother. 42 (1998) 321-331